<DOC>
	<DOCNO>NCT01355276</DOCNO>
	<brief_summary>The purpose study compare Cinitapride tablets domperidone tablet ( motilium ) , evaluate efficacy safety Cinitapride tablets treatment mild moderate functional dyspepsia .</brief_summary>
	<brief_title>Efficacy Safety Cinitapride Tablets Treatment Mild Moderate Functional Dyspepsia</brief_title>
	<detailed_description />
	<mesh_term>Dyspepsia</mesh_term>
	<mesh_term>Domperidone</mesh_term>
	<criteria>Inclusion : 1 . Aged 18~65 year , male female ; 2 . Patients symptoms mild moderate functional dyspepsia ; 3 . Symptoms related dyspepsia develop 6 month ago early satiety or/and discomfort meal develop past 3 month ; 4 . Gastrointestinal malignancy , peptic ulcer , liver , gallbladder pancreas diseases excluded gastroscopy , Bultrasonography laboratory examination within 4 week prior administration ( endoscopy result consider clinically unrelated exclude , small hiatal hernia chronic nonatrophic pangastritis ) ; 5 . Patient sign informed consent form . Exclusion criteria 1 . Patients gastroesophageal reflux and/or irritable bowel syndrome ; 2 . Acid regurgitation per week ; 3 . Previously receive abdominal surgery ( except appendectomy herniorrhaphy ) ; 4 . A history gastric duodenal ulcer ; 5 . Patients depression anxiety neurosis ; 6 . Patients arrhythmia ; 7 . QTc 0.5s ; 8 . Hepatic renal insufficiency : AST or/and ALT equal 1.5 time upper normal limit ; Cr upper normal limit ; 9 . Pathological lactorrhea ; 10 . Patients alcohol abuse ( daily alcohol intake 40g ) , drug dependence neuropsychiatric disorder difficult control , well others appropriate participate drug trial ; 11 . Pregnant lactating woman ; 12 . Patients require therapy change gastrointestinal mobility ; 13 . Patients participate participated drug clinical trial within 3 month prior entry ; 14 . Known allergic cinitapride ; Patients consider investigator inappropriate participate .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2011</verification_date>
	<keyword>Cinitapride</keyword>
	<keyword>efficacy</keyword>
	<keyword>safety</keyword>
	<keyword>mild moderate functional dyspepsia</keyword>
</DOC>